BL-ARC002 in Esophageal Squamous Cell Carcinoma: NCT07763652 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Not yet recruiting
Recruitment status
22
Planned enrollment
2028-12-01
Primary-completion proxy
Executive view
NCT07763652 evaluates BL-ARC002 in Esophageal Squamous Cell Carcinoma. The disclosed sponsor is Sichuan Baili Pharmaceuticals Co.,Ltd, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Phase Ia: Dose limiting toxicity (DLT), assessed over Up to 42 days after the first dose.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07763652 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Esophageal Squamous Cell Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for BL-ARC002, while Company & Deal Intelligence MCP organization_fetch was queried for Sichuan Baili Pharmaceuticals Co.,Ltd.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07763652 | BL-ARC002 | Phase 1 / Not yet recruiting | Sichuan Baili Pharmaceuticals Co.,Ltd | China | Phase Ia: Dose limiting toxicity (DLT) Up to 42 days after the first dose | 2028-12-01 |
| NCT07770113 | Apatinib Mesylate | Phase 2 / Recruiting | The First Affiliated Hospital of Zhengzhou University | China | Median progression-free survival The time from the first day of medication to disease progression or d… | 2026-11-30 |
| NCT07768514 | Acetaminophen/Ibuprofen | Phase 2 / Active, not recruiting | Seoul National University Bundang Hospital | South Korea | Sum of Pain Intensity Differences Over 72 Hours (SPID72) From immediately after surgery through 72 hours after surgery | 2026-11-08 |
| NCT07763171 | Tislelizumab | Phase 3 / Not yet recruiting | Gruppo Oncologico del Nord-Ovest | Italy, Germany, Spain | Progression-free survival 36 months | 2029-09-01 |
| NCT07757191 | tPA/HisproUK(Thrombolytic Science International LLC) | Phase 2 / Not yet recruiting | Taipei Veterans General Hospital | Taiwan Province | Pathological complete response (pCR) rate From enrollment to the end of surgical treatment. | 2028-09-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07763652 is a Phase 1, not yet recruiting study with 22 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Phase Ia: Dose limiting toxicity (DLT)” over “Up to 42 days after the first dose.” The retrieved endpoint description is: DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 22 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
2 recent result records were selected as contextual evidence for Esophageal Squamous Cell Carcinoma. These records do not establish direct evidence for NCT07763652 unless the registration number matches.
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy Wit…
Phase 1/2; n=71; Number of Participants experiencing AEs = 27 Participants ; Number of Participants experiencing AEs = 14 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04276493
Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Phase 2; n=19; OS(Median) = 7.6 Months (95% Confidence Interval, NA - NA); OS(Median) = 9.5 Months (95% Confidence Interval, 4.6 - 21.6) Source: https://clinicaltrials.gov/ct2/show/results/NCT04209686
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
BL-ARC002 is indexed as Radiopharmaceuticals and diagnostic agent with target not reported biology and a global stage of Phase 1. The asset profile lists Sichuan Biokin Pharmaceutical Co., Ltd. as an originator or developer.
Sichuan Baili Pharmaceuticals Co.,Ltd is indexed in China with the website http://www.baili-pharm.com. The organization record is used to resolve sponsor identity. The record lists 29 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether BL-ARC002 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07763652
Protocol source: https://clinicaltrials.gov/study/NCT07763652
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
BL-ARC002 in Esophageal Squamous Cell Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Phase Ia: Dose limiting toxicity (DLT) and 2028-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
